DREAM is reduced in synovial fibroblasts of patients with chronic arthritic pain: is it a suitable target for peripheral pain management?
2008

DREAM and Chronic Arthritic Pain

Sample size: 53 publication 10 minutes Evidence: moderate

Author Information

Author(s): Nataša Reisch, Andreas Engler, André Aeschlimann, Beat R. Simmen, Beat A. Michel, Renate E. Gay, Steffen Gay, Haiko Sprott

Primary Institution: University Hospital Zurich

Hypothesis

Does DREAM play a role in the regulation of pdyn expression in chronic pain patients?

Conclusion

DREAM does not qualify as a target for peripheral pain management in osteoarthritis patients.

Supporting Evidence

  • DREAM mRNA expression was significantly reduced in OA patients with chronic pain.
  • Inhibiting DREAM expression did not lead to significant changes in pdyn and c-fos expression.
  • DREAM was detected on the mRNA level in both OA SFLCs and PBMCs.

Takeaway

DREAM is a protein that might help with pain, but in people with arthritis, it doesn't seem to work as we hoped.

Methodology

The study measured DREAM expression in synovial fibroblast-like cells and peripheral blood mononuclear cells using real-time PCR and siRNA.

Limitations

The study did not detect pdyn expression in PBMCs, and the role of DREAM in pain management remains unclear.

Participant Demographics

53 OA patients (23 females, 30 males) and 26 healthy controls.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1186/ar2431

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication